Mitigation and Management of Ocular Toxicity in Patients Receiving Antibody–Drug Conjugates

Learn how ophthalmologists and optometrists can work with hematologist/oncologists to recognize and optimally manage ocular toxicities in patients receiving antibody–drug conjugates for the treatment of cancer with expert slides and on-demand Webcast capturing a live CCO Webinar, plus a focused expert-authored commentary.
Asim V. Farooq, MD
Program Director
Sagar Lonial, MD
Anthony Perissinotti, PharmD, BCOP

Webcast

Watch this on-demand Webcast capturing expert presentations focused on the mechanism of corneal toxicity in patients with cancer receiving antibody–drug conjugates and strategies for optimal monitoring and management.

Asim V. Farooq, MD
Program Director
Sagar Lonial, MD Anthony Perissinotti, PharmD, BCOP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 20, 2021 Expired: January 19, 2022
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue